National Institute for Health and Care Excellence6d
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284
Suggested remit: To appraise the clinical and cost effectiveness of sebetralstat within its marketing authorisation for treating acute attacks of hereditary angioedema.
National Institute for Health and Care Excellence7d
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]
Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has ...
National Institute for Health and Care Excellence11d
Guidance, NICE advice and quality standards In development
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202 Technology appraisal guidance TBC Guselkumab for previously treated moderately to ...
National Institute for Health and Care Excellence13d
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
For information, the company have announced that Tecentriq did not meet its primary endpoint during the Phase 3 trial and therefore they will no longer be pursuing a Marketing Authorisation ...
National Institute for Health and Care Excellence1d
Guidance, NICE advice and quality standards In development
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280] Technology appraisal guidance 12 February 2025 Abaloparatide for treating ...
National Institute for Health and Care Excellence11d
Guidance, NICE advice and quality standards In development
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284 Technology appraisal guidance TBC Secukinumab for treating enthesitis-related arthritis or juvenile ...
National Institute for Health and Care Excellence7d
Guidance and quality standards In consultation
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment Draft guidance Health technology evaluation 8 July 2024 12 SQ-HDM SLIT for ...
National Institute for Health and Care Excellence7d
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
22 November 2022 Scope consultation end date extended by one week from 24/11/2022 until 01/12/2022. For further information on the guideline development process, please see how we develop NICE ...
National Institute for Health and Care Excellence11d
Guidance, NICE advice and quality standards In development
Tenecteplase for treating acute ischaemic stroke [ID6306] Technology appraisal guidance 24 July 2024 Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of ...
National Institute for Health and Care Excellence9d
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence6d
Guidance, NICE advice and quality standards In development
Renal cell carcinoma Pathways Pilot [ID6186] Technology appraisal guidance TBC Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277] Technology appraisal guidance TBC ...
National Institute for Health and Care Excellence11d
Guidance and quality standards In consultation
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction Interventional procedure consultation Interventional procedures guidance 28 June 2024 Direct skeletal fixation of limb or ...